You save $69.98
CRISC Premium Bundle
- Premium File 1105 Questions & Answers
- Last Update: Nov 10, 2026
- Training Course 64 Lectures
- Study Guide 498 Pages
You save $69.98
An organization is preventing a recurrence of this risk pattern: A team reports a low risk level because MFA is deployed but labels that number 'inherent risk.' Which ongoing safeguard would best prevent recurrence of this specific failure mode?
Make inherent and residual ratings separate required assessment fields. This safeguard addresses the recurring failure rather than only the current event. The expected verification is: Risk documentation presents inherent rating, MFA effectiveness evidence, residual rating, and any remaining gaps.
Require architecture mapping before approving assessment scope. That safeguard prevents failures associated with assessment scope dispute and does not directly prevent this inherent versus residual recurrence. The applicable continuing control is: Make inherent and residual ratings separate required assessment fields.
Require action completeness fields before changing risk status to treated. That safeguard prevents failures associated with risk action traceability and does not directly prevent this inherent versus residual recurrence. The applicable continuing control is: Make inherent and residual ratings separate required assessment fields.
Maintain supplier assessment standards tied to service criticality tiers. That safeguard prevents failures associated with supplier scoring baseline and does not directly prevent this inherent versus residual recurrence. The applicable continuing control is: Make inherent and residual ratings separate required assessment fields.
A risk leader is reviewing this situation: A new endpoint protection tool was purchased, and leadership immediately assumes residual ransomware risk has fallen. Which next step would most directly treat or govern the risk in this situation?
Reassess residual risk only after validating coverage, operation and relevant detection performance. Control acquisition does not equal effective risk reduction; actual operation determines residual exposure. Evidence that the action has worked would be: Evidence shows installed coverage, tested detections, response times, and a revised residual risk rating.
Add measurable response actions, owner, due date, residual exposure, and evidence requirements. That change is aimed at risk action traceability, whereas this decision must address control effectiveness evidence. The relevant first comparison is: Review deployment telemetry and controlled testing before changing the residual rating.
Perform scenario and sensitivity analysis over credible durations and recovery costs before choosing treatment. That change is aimed at scenario sensitivity analysis, whereas this decision must address control effectiveness evidence. The relevant first comparison is: Review deployment telemetry and controlled testing before changing the residual rating.
Reassess current exposure and escalate expired acceptance to the designated risk owner for renewal or remediation. That change is aimed at risk register exception expiry, whereas this decision must address control effectiveness evidence. The relevant first comparison is: Review deployment telemetry and controlled testing before changing the residual rating.
A risk owner seeks evidence following review of this situation: A new endpoint protection tool was purchased, and leadership immediately assumes residual ransomware risk has fallen. Which evidence would best demonstrate that the intended risk response is functioning?
Evidence shows installed coverage, tested detections, response times, and a revised residual risk rating. This evidence addresses the stated risk rather than showing only that a control was configured. Control acquisition does not equal effective risk reduction; actual operation determines residual exposure.
The register traces each risk to approved action, status, testing, and residual acceptance. That observation may help validate risk action traceability, but it does not establish the acceptance condition for control effectiveness evidence. Here, the decisive evidence is: Evidence shows installed coverage, tested detections, response times, and a revised residual risk rating.
Recovery tests separately measure elapsed restoration time and age of recovered transactions. That observation may help validate rto and rpo distinction, but it does not establish the acceptance condition for control effectiveness evidence. Here, the decisive evidence is: Evidence shows installed coverage, tested detections, response times, and a revised residual risk rating.
Independent reviewers produce comparable ratings for a shared reference scenario. That observation may help validate risk assessment consistency, but it does not establish the acceptance condition for control effectiveness evidence. Here, the decisive evidence is: Evidence shows installed coverage, tested detections, response times, and a revised residual risk rating.
A governance team is discussing the underlying cause in this situation: A new endpoint protection tool was purchased, and leadership immediately assumes residual ransomware risk has fallen. Which risk-management principle most directly explains the correct approach?
Control acquisition does not equal effective risk reduction; actual operation determines residual exposure. The immediate management action is: Reassess residual risk only after validating coverage, operation and relevant detection performance.
Emerging technology risk requires an explicit attack/operational path and business consequence. That principle is relevant to ai model poisoning exposure, not the mechanism implicated by the stated control effectiveness evidence situation. In this case: Control acquisition does not equal effective risk reduction; actual operation determines residual exposure.
Risk acceptance is contextual and time bounded; expired decisions need renewed governance. That principle is relevant to risk register exception expiry, not the mechanism implicated by the stated control effectiveness evidence situation. In this case: Control acquisition does not equal effective risk reduction; actual operation determines residual exposure.
Risk scope must cover plausible exposure paths, even when organizational ownership is fragmented. That principle is relevant to assessment scope dispute, not the mechanism implicated by the stated control effectiveness evidence situation. In this case: Control acquisition does not equal effective risk reduction; actual operation determines residual exposure.
A risk committee is deciding whether an unresolved exposure can be tolerated: A new endpoint protection tool was purchased, and leadership immediately assumes residual ransomware risk has fallen. What is the most relevant avoidable consequence if the weakness remains unresolved?
Premature risk reduction can cause management to withdraw needed compensating controls. This consequence follows from the specific missing governance or technical safeguard. Control acquisition does not equal effective risk reduction; actual operation determines residual exposure. The appropriate response is: Reassess residual risk only after validating coverage, operation and relevant detection performance.
Omitted vendor downtime can cause missed claims obligations without a funded recovery response. That potential consequence concerns outsourced service impact, rather than the direct risk described by control effectiveness evidence. Here the material exposure is: Premature risk reduction can cause management to withdraw needed compensating controls.
False numerical precision can lead to unjustified acceptance or misallocation of controls. That potential consequence concerns uncertainty in assessment, rather than the direct risk described by control effectiveness evidence. Here the material exposure is: Premature risk reduction can cause management to withdraw needed compensating controls.
Vague remediation notes permit overdue exposures to be reported as managed. That potential consequence concerns risk action traceability, rather than the direct risk described by control effectiveness evidence. Here the material exposure is: Premature risk reduction can cause management to withdraw needed compensating controls.
Before making a treatment decision, an analyst is investigating this situation: A new endpoint protection tool was purchased, and leadership immediately assumes residual ransomware risk has fallen. Which targeted first investigation would best clarify the risk before action is approved?
Review deployment telemetry and controlled testing before changing the residual rating. This isolates the relevant cause before changing unrelated controls. An appropriate follow-up is: Reassess residual risk only after validating coverage, operation and relevant detection performance.
Review scoring definitions and the assumptions behind the conflicting ratings. That investigation concerns risk assessment consistency and would not isolate the first implicated dependency here. The targeted check is: Review deployment telemetry and controlled testing before changing the residual rating.
Compare backup intervals, actual restore points, and payroll posting frequencies. That investigation concerns rto and rpo distinction and would not isolate the first implicated dependency here. The targeted check is: Review deployment telemetry and controlled testing before changing the residual rating.
Review latency, error, saturation, and recent changes during the promotional window. That investigation concerns cloud service capacity event and would not isolate the first implicated dependency here. The targeted check is: Review deployment telemetry and controlled testing before changing the residual rating.
An organization is preventing a recurrence of this risk pattern: A new endpoint protection tool was purchased, and leadership immediately assumes residual ransomware risk has fallen. Which ongoing safeguard would best prevent recurrence of this specific failure mode?
Require post-deployment validation before closing risk actions. This safeguard addresses the recurring failure rather than only the current event. The expected verification is: Evidence shows installed coverage, tested detections, response times, and a revised residual risk rating.
Require action completeness fields before changing risk status to treated. That safeguard prevents failures associated with risk action traceability and does not directly prevent this control effectiveness evidence recurrence. The applicable continuing control is: Require post-deployment validation before closing risk actions.
Require architecture mapping before approving assessment scope. That safeguard prevents failures associated with assessment scope dispute and does not directly prevent this control effectiveness evidence recurrence. The applicable continuing control is: Require post-deployment validation before closing risk actions.
Include key suppliers in BIA validation and resilience exercises. That safeguard prevents failures associated with outsourced service impact and does not directly prevent this control effectiveness evidence recurrence. The applicable continuing control is: Require post-deployment validation before closing risk actions.
A risk leader is reviewing this situation: A payments team implements tokenization but still sees unusually high privileged-access loss exposure beyond tolerance. Which next step would most directly treat or govern the risk in this situation?
Calculate residual exposure after tokenization and escalate any remaining tolerance breach to the authorized risk owner. Residual risk remains relevant even when a strong preventive control mitigates one failure path. Evidence that the action has worked would be: The signed risk record shows residual risk with evidence and a formal treatment or acceptance decision.
Reassess current exposure and escalate expired acceptance to the designated risk owner for renewal or remediation. That change is aimed at risk register exception expiry, whereas this decision must address residual-risk acceptance limit. The relevant first comparison is: Separate token-protected storage exposure from remaining privileged access paths.
Assess both restoration-time and tolerable data-loss objectives with payroll and recovery owners. That change is aimed at rto and rpo distinction, whereas this decision must address residual-risk acceptance limit. The relevant first comparison is: Separate token-protected storage exposure from remaining privileged access paths.
Map trust boundaries and likely token misuse paths before evaluating exposure and selecting protections. That change is aimed at threat modeling trust boundaries, whereas this decision must address residual-risk acceptance limit. The relevant first comparison is: Separate token-protected storage exposure from remaining privileged access paths.
A risk owner seeks evidence following review of this situation: A payments team implements tokenization but still sees unusually high privileged-access loss exposure beyond tolerance. Which evidence would best demonstrate that the intended risk response is functioning?
The signed risk record shows residual risk with evidence and a formal treatment or acceptance decision. This evidence addresses the stated risk rather than showing only that a control was configured. Residual risk remains relevant even when a strong preventive control mitigates one failure path.
Register entries reconcile the common scenario, assigned ownership, treatments, and residual risk. That observation may help validate risk register duplicate ownership, but it does not establish the acceptance condition for residual-risk acceptance limit. Here, the decisive evidence is: The signed risk record shows residual risk with evidence and a formal treatment or acceptance decision.
Management receives a risk estimate with its confidence limits and prioritized evidence gaps. That observation may help validate uncertainty in assessment, but it does not establish the acceptance condition for residual-risk acceptance limit. Here, the decisive evidence is: The signed risk record shows residual risk with evidence and a formal treatment or acceptance decision.
The signed BIA establishes maximum tolerable disruption, critical transaction windows, and recovery priorities. That observation may help validate business impact sequence, but it does not establish the acceptance condition for residual-risk acceptance limit. Here, the decisive evidence is: The signed risk record shows residual risk with evidence and a formal treatment or acceptance decision.
A governance team is discussing the underlying cause in this situation: A payments team implements tokenization but still sees unusually high privileged-access loss exposure beyond tolerance. Which risk-management principle most directly explains the correct approach?
Residual risk remains relevant even when a strong preventive control mitigates one failure path. The immediate management action is: Calculate residual exposure after tokenization and escalate any remaining tolerance breach to the authorized risk owner.
Risk scope must cover plausible exposure paths, even when organizational ownership is fragmented. That principle is relevant to assessment scope dispute, not the mechanism implicated by the stated residual-risk acceptance limit situation. In this case: Residual risk remains relevant even when a strong preventive control mitigates one failure path.
Integrity events can cause business loss even when payment systems remain available. That principle is relevant to payment integrity event, not the mechanism implicated by the stated residual-risk acceptance limit situation. In this case: Residual risk remains relevant even when a strong preventive control mitigates one failure path.
External service dependencies affect business impact even when infrastructure is not owned internally. That principle is relevant to outsourced service impact, not the mechanism implicated by the stated residual-risk acceptance limit situation. In this case: Residual risk remains relevant even when a strong preventive control mitigates one failure path.
A risk committee is deciding whether an unresolved exposure can be tolerated: A payments team implements tokenization but still sees unusually high privileged-access loss exposure beyond tolerance. What is the most relevant avoidable consequence if the weakness remains unresolved?
Assuming one control eliminates all risk can leave privileged misuse unaddressed. This consequence follows from the specific missing governance or technical safeguard. Residual risk remains relevant even when a strong preventive control mitigates one failure path. The appropriate response is: Calculate residual exposure after tokenization and escalate any remaining tolerance breach to the authorized risk owner.
Carrying forward expired acceptance can leave changed threats unaddressed. That potential consequence concerns risk register exception expiry, rather than the direct risk described by residual-risk acceptance limit. Here the material exposure is: Assuming one control eliminates all risk can leave privileged misuse unaddressed.
Assuming all partner tokens are trustworthy may permit privilege escalation through forged or overbroad claims. That potential consequence concerns threat modeling trust boundaries, rather than the direct risk described by residual-risk acceptance limit. Here the material exposure is: Assuming one control eliminates all risk can leave privileged misuse unaddressed.
Acting on one optimistic estimate can underfund protection against prolonged interruption. That potential consequence concerns scenario sensitivity analysis, rather than the direct risk described by residual-risk acceptance limit. Here the material exposure is: Assuming one control eliminates all risk can leave privileged misuse unaddressed.
or Guarantee your success by buying the full version which covers the full latest pool of questions. (1105 Questions, Last Updated on Nov 10, 2026)
Please check your mailbox for a message from support@examlabs.com and follow the directions.